Zydus Lifesciences gets USFDA’s tentative approval for Letermovir Tablets

23 Mar 2024 Evaluate

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Letermovir tablets, 240 mg and 480 mg, (USRLD: Prevymis tablets). 

Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received a bone marrow transplant or kidney transplant. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. Letermovir tablets, 240 mg and 480 mg had annual sales of $289.5 million in the United States (IQVIA MAT Jan-24). 

The group now has 393 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

965.50 17.60 (1.86%)
29-Apr-2024 10:34 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.65
Dr. Reddys Lab 6269.65
Cipla 1399.40
Zydus Lifesciences 965.50
Lupin 1636.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.